CJC-1295 (No DAC) and CJC-1295 + Ipamorelin: What Combination Research Shows
Investigating growth hormone secretagogue pathways often requires evaluating distinct receptor signaling mechanisms in combination. This technical review examines the preclinical data surrounding CJC-1295 (No DAC) alone and alongside Ipamorelin, detailing dual receptor kinetics, in vitro assay design, and laboratory handling considerations.
Quick answer
Investigating growth hormone secretagogue pathways often requires evaluating distinct receptor signaling mechanisms in combination. This technical review examines the preclinical data surrounding CJC-1295 (No DAC) alone and alongside Ipamorelin, detailing dual receptor kinetics, in vitro assay design, and laboratory handling considerations.
Key takeaways
- In neuroendocrine research, growth hormone (GH) secretion is governed by a tightly regulated dual-receptor signaling framework located within anterior pituitary somatotrophs.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC), also classified as Tetrasubstituted GRF 1-29, is a synthetic 29-amino-acid peptide analog of native GHRH.
- To achieve heightened somatotroph stimulation in vitro, researchers often combine a GHRH analog with a ghrelin receptor agonist such as [Ipamorelin](/product/ipamorelin).
- Preclinical studies in rodent models demonstrate that combining GHRH derivatives with ghrelin mimetics amplifies systemic GH pulse amplitude without inducing continuous, non-pulsatile GH elevation.
Overview of Growth Hormone Axis Secretagogues in Laboratory Models
In neuroendocrine research, growth hormone (GH) secretion is governed by a tightly regulated dual-receptor signaling framework located within anterior pituitary somatotrophs. Investigators frequently utilize synthetic peptides to probe these pathways, isolating specific receptor interactions to observe downstream somatotropic activity. Among these tools, modified growth hormone-releasing hormone (GHRH) analogs and selective growth hormone secretagogue receptor (GHSR-1a) agonists serve as primary instruments for mapping hormone pulsatility, somatotroph responsiveness, and peripheral signaling.
When designing preclinical assays, understanding how discrete peptide classes modulate somatotroph activity is critical. Single-agent assays illuminate direct receptor transduction pathways, while dual-agent paradigms evaluate cross-talk and potentiated GH release. Within our catalog of research peptides, synthetic ligands are characterized by specific structural modifications that alter plasma half-life, enzymatic degradation resistance, and receptor binding affinity.
Molecular Structure and Pharmacodynamics of CJC-1295 (No DAC)
CJC-1295 (No DAC), also classified as Tetrasubstituted GRF 1-29, is a synthetic 29-amino-acid peptide analog of native GHRH. Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, this compound incorporates four specific amino acid substitutions (Ala2, Gln8, Ala15, and Leu27) relative to the truncated native peptide sequence. These structural modifications significantly reduce susceptibility to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending its functional half-life compared to unmodified GHRH 1-29.
In cell culture models, CJC-1295 (No DAC) binds directly to the growth hormone-releasing hormone receptor (GHRH-R), a G-protein coupled receptor (GPCR) paired with the Gαs subunit. Ligand binding activates adenylate cyclase, triggering an intracellular cascade that increases cyclic adenosine monophosphate (cAMP) levels and stimulates protein kinase A (PKA). Preclinical rodent and cell culture studies confirm that this pathway drives both the transcription of growth hormone mRNA and the exocytosis of stored GH granules without altering native pituitary feedback loops.
Mechanistic Synergy: Combining GHRH-R and GHSR-1a Agonism
To achieve heightened somatotroph stimulation in vitro, researchers often combine a GHRH analog with a ghrelin receptor agonist such as Ipamorelin. While CJC-1295 (No DAC) operates via the GHRH-R/cAMP pathway, Ipamorelin is a pentapeptide that selectively targets the Growth Hormone Secretagogue Receptor 1a (GHSR-1a). Receptor binding at GHSR-1a triggers a distinct Gαq-coupled intracellular cascade, activating phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), and inducing the mobilization of intracellular calcium (Ca2+).
When somatotroph cultures are exposed to both CJC-1295 (no dac) and cjc-1295 + ipamorelin receptor agonists concurrently, the simultaneous elevation of intracellular cAMP and intracellular calcium produces a synergistic secretagogue effect. In vitro electrophysiological data indicate that concurrent activation releases significantly greater concentrations of growth hormone than the mathematical sum of either agent administered independently. This complementary mechanism allows researchers to investigate maximum somatotroph secretory capacity while maintaining baseline physiological sensitivity.
Evaluating Preclinical Data: Where Combination Research Stands
Preclinical studies in rodent models demonstrate that combining GHRH derivatives with ghrelin mimetics amplifies systemic GH pulse amplitude without inducing continuous, non-pulsatile GH elevation. This preservation of pulsatility is important in tissue repair research, as tissue responsiveness and peripheral receptor sensitivity rely heavily on episodic signaling rather than constant target receptor saturation. Furthermore, animal assays suggest that dual stimulation leads to sustained elevations in circulating insulin-like growth factor 1 (IGF-1) concentrations over 24- to 48-hour observation windows.
However, researchers must carefully delineate where verified experimental data ends. While the synergistic mechanisms of GHRH-R and GHSR-1a co-activation are well documented in rodent somatotroph cultures and porcine pituitary explants, direct comparative trial data for specific pre-mixed formulations remain limited in formal literature. Many combination observations are derived from parallel single-agent dosing assays rather than fixed-ratio co-formulations. Consequently, researchers studying dual mechanisms must establish baseline single-agent controls within their specific assay designs to accurately quantify additive versus synergistic effects.
Comparative Analysis: Secretagogue Profiles in Laboratory Settings
Selecting appropriate secretagogues for endocrine assay modeling depends on the specific receptor dynamics required by the hypothesis. CJC-1295 (No DAC) provides a sustained, physiological GHRH signal with an in vitro half-life of approximately 30 minutes, whereas unmodified GRF 1-29 degrades within minutes. When compared to other GHRH derivatives like Sermorelin, CJC-1295 (No DAC) demonstrates enhanced metabolic stability due to its tetrasubstituted design.
Similarly, when contrasted with Tesamorelin—a GHRH analog possessing a hexenoyl moiety designed for specific hepatic metabolic assays—CJC-1295 (No DAC) presents a distinct affinity profile suitable for generalized pituitary secretion studies. Combining CJC-1295 (No DAC) with Ipamorelin offers a highly selective experimental tool, as Ipamorelin lacks the cross-reactivity with adrenocorticotropic hormone (ACTH) or prolactin receptors seen with earlier ghrelin mimetics like GHRP-2 or GHRP-6. Detailed comparative pathways are indexed across our peptide research library.
Downstream Signaling Cascades and IGF-1 Upregulation in Preclinical Models
The primary downstream marker of somatotropic activation in animal models is the hepatic synthesis and release of IGF-1. Following GH binding to hepatic growth hormone receptors (GHR), the JAK2/STAT5b signaling pathway is activated, initiating gene transcription for IGF-1 and its primary binding protein, IGFBP-3. In cell culture and animal models, sustained pulsatile GH release stimulated by CJC-1295 (No DAC) correlates directly with upregulated IGF-1 mRNA expression in hepatic parenchymal cells.
In preclinical paradigms focusing on tissue repair, localized IGF-1 expression drives cellular proliferation, extracellular matrix remodeling, and satellite cell activation in skeletal muscle tissue. In vitro wound-healing assays demonstrate that media conditioned by somatotrophs stimulated with dual secretagogues accelerates keratinocyte migration and fibroblast proliferation compared to baseline controls. These observations underline the utility of CJC-1295 (No DAC) and Ipamorelin as model reagents for studying somatic repair cascades.
In Vitro Assay Design and Microfluidic Perfusions
Modern neuroendocrine research frequently utilizes microfluidic cell culture platforms and perifusion systems to measure rapid changes in hormone secretion. When designing assays to test CJC-1295 (no dac) and cjc-1295 + ipamorelin exposure profiles, primary anterior pituitary cells are cultured on microcarrier beads or within microfluidic channels, allowing real-time sampling of effluent media following peptide administration.
Experimental parameters generally evaluate pulse frequency, peak magnitude, and duration of GH release. Researchers typically introduce peptides at nanomolar to micromolar concentrations, measuring downstream cAMP accumulation via immunoassay and intracellular Ca2+ flux via fluorescent indicator dyes (such as Fura-2 AM). Inclusion of specific receptor antagonists—such as GHRH receptor antagonists or GHSR-1a blockers—helps confirm that observed responses result purely from targeted receptor interaction rather than non-specific membrane depolarization.
Laboratory Reconstitution Protocols: Co-Reconstitution vs. Separate Handling
Proper reconstitution is critical to maintaining peptide integrity and obtaining reproducible experimental outcomes. Researchers routinely utilize our online reconstitution calculator to determine precise solvent volumes, molarities, and final working concentrations. Standard laboratory protocols require dissolving lyophilized powders in sterile, bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS, pH 7.4) under a laminar flow hood.
A key methodological decision in dual secretagogue assays is whether to reconstitute peptides separately or co-reconstitute them in a single vial. Reconstituting CJC-1295 (No DAC) and Ipamorelin separately is generally recommended for analytical precision. Separate stock solutions allow investigators to independently adjust the molar ratios of each peptide during assay execution, accounting for variations in receptor density or binding kinetics. If co-reconstitution is necessary for specific automated liquid handling systems, the combined solution must be evaluated immediately via HPLC to verify that no intermolecular aggregation or pH-dependent degradation occurs.
Stability, Storage, and Chemical Degradation Mitigation
Lyophilized research peptides must be stored under controlled conditions to preserve secondary structure and prevent hydrolytic or oxidative degradation. Unopened vials containing lyophilized CJC-1295 (No DAC) or Ipamorelin should be stored in a desiccant-equipped freezer at -20°C or -80°C, where they remain stable for up to 24 months. Avoid subjecting lyophilized materials to repeated freeze-thaw cycles, as moisture condensation can induce rapid degradation.
Once reconstituted into aqueous solution, peptide stock aliquots should be stored at 2°C to 8°C for short-term assays (up to 5–7 days) or quick-frozen in single-use working volumes at -80°C for extended research schedules. Reconstituted peptides are sensitive to agitation, photolysis, and thermal fluctuations; solutions should never be vortexed vigorously. Laboratory procedures should specify gentle inversion to achieve complete dissolution without introducing mechanical shear stress.
Analytical Integrity and Quality Assurance Standards at PX1 Research
Rigorous research outcomes depend on high-purity reagents verified by robust analytical methods. Every lot of CJC-1295 (No DAC) and Ipamorelin supplied by PX1 Research undergoes stringent quality control testing in an ISO 17025 accredited laboratory located in the United States. Purity profiles are confirmed using High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (MS) to guarantee molecular identity, correct sequence mass, and chemical purity exceeding 99.0%.
In addition to structural verification, all lots undergo kinetic chromogenic limulus amebocyte lysate (LAL) testing to confirm that endotoxin levels remain strictly below regulatory thresholds (<0.01 EU/mg). This level of quality assurance prevents endotoxin-induced inflammatory responses in cell cultures or animal models, protecting assay validity. Institutional buyers seeking verified documentation can inspect a batch-specific certificate of analysis (COA) prior to acquisition or contact our team regarding bulk lab account services.
Frequently Asked Questions
What is the structural difference between CJC-1295 (No DAC) and CJC-1295 with DAC?
CJC-1295 (No DAC), also known as Modified GRF 1-29, consists of 29 amino acids with four structural substitutions that prevent enzymatic cleavage by DPP-IV. CJC-1295 with DAC includes an additional Lysine residue attached to a Drug Affinity Complex (DAC) maleimide moiety, which covalently binds to circulating albumin in vivo to drastically extend systemic circulation time. CJC-1295 (No DAC) exhibits a significantly shorter biological half-life, allowing researchers to study physiological pulsatile GH release rather than continuous receptor exposure.
Why do researchers study CJC-1295 (No DAC) alongside Ipamorelin?
Researchers investigate CJC-1295 (No DAC) and Ipamorelin together because they target two distinct, complementary receptors on anterior pituitary somatotrophs. CJC-1295 (No DAC) activates the GHRH receptor to elevate intracellular cAMP, while Ipamorelin activates the GHSR-1a receptor to elevate intracellular calcium. Co-activation produces a synergistic increase in growth hormone transcription and release in preclinical models that exceeds the additive effects of either peptide alone.
How should CJC-1295 (No DAC) and Ipamorelin be stored upon arrival?
Lyophilized vials should be stored at -20°C or -80°C in a dry environment away from light. Under these conditions, the dry peptide powder remains stable for up to 24 months. After reconstitution with sterile aqueous solvents, stock solutions should be stored at 2°C to 8°C for up to 7 days, or aliquoted into single-use volumes and frozen at -80°C to prevent degradation from repeated freeze-thaw cycles.
Is co-reconstituting CJC-1295 (No DAC) and Ipamorelin in the same vial recommended?
While co-reconstitution is physically possible in compatible buffers such as sterile bacteriostatic water, reconstituting each peptide in separate vials is generally recommended for rigorous laboratory research. Separate preparation allows researchers to independently vary molar ratios during assays, precise quantification of individual component concentrations, and elimination of potential peptide-peptide interactions in concentrated stock solutions.
What endotoxin testing standards apply to PX1 Research peptides?
All PX1 Research compounds undergo quantitative chromogenic LAL assays to verify endotoxin levels below 0.01 EU/mg. Low endotoxin levels are vital for in vitro cell culture work and preclinical tissue assays to ensure that observed biological responses are not confounded by lipopolysaccharide (LPS) contamination or inflammatory signaling.
What tools are available to assist with laboratory concentration calculations?
PX1 Research provides an interactive online reconstitution calculator designed for laboratory personnel. This tool computes accurate solvent volumes required to reach target molarities or milligram-per-milliliter concentrations based on specific vial mass and solvent selection.
What receptor cross-reactivity does Ipamorelin display compared to other secretagogues?
Ipamorelin is recognized for high receptor selectivity towards GHSR-1a. Unlike earlier ghrelin mimetics such as GHRP-2 or GHRP-6, preclinical assays show that Ipamorelin does not induce significant secondary stimulation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, making it an ideal selective agent for isolated GH axis research.
Are PX1 Research compounds intended for clinical or human trial use?
No. All products supplied by PX1 Research are strictly synthesized and sold for in vitro, biochemical, and preclinical laboratory research use only. They are not intended, approved, or formulated for human, veterinary, therapeutic, or clinical applications.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.